BioCentury
ARTICLE | Company News

Numab, Ono deal

March 31, 2017 6:35 PM UTC

Numab granted Ono exclusive rights to develop and commercialize a multispecific immuno-oncology antibody to be identified using Numab’s discovery platform. Ono also received an option to acquire IP rights to the compound. Numab’s platform is designed to stabilize antibody domains by exchanging an unstable part of the antibody scaffold’s kappa chain with a lambda cap sequence. The companies said the compound will “exploit one of Ono’s novel therapeutic approaches in immuno-oncology” and could include combinations with Ono’s Opdivo nivolumab. Ono shares rights to cancer drug Opdivo with Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.). Opdivo is a human IgG4 mAb against PD-1. ...